EDAP TMS S.A. ( FOCL ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Presentation Unknown Analyst Welcome, everybody.
EDAP's fundamentals have deteriorated sharply: revenue plunged 56.9% to $6.9M in 2026Q2 while total debt jumped roughly 18-fold from $2.3M to $41.7M in a single quarter, pushing equity to -$3.2M and leaving cash of just $11.8M.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.10+44.4% vs -$0.18 | $10M-11.4% vs $11M |
Q3 2026 Aug 13, 2026 | -$0.39-95.0% vs -$0.20 | $13M-12.5% vs $15M |
Q2 2026 May 7, 2026 | -$0.24-17.1% vs -$0.20 | $18M+7.4% vs $17M |
Q2 2026 Mar 25, 2026 | -$0.25-72.3% vs -$0.15 | $22M+2.6% vs $21M |
EDAP TMS S.A. ( FOCL ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Presentation Unknown Analyst Welcome, everybody.
EDAP TMS S.A. ( FOCL ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants Louisa Smith - Gilmartin Group LLC Alexander Nowak - Lucid Capital Markets, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Presentation Operator Greetings, and welcome to the FocalTherics Third Quarter 2026 Conference Call.
FocalTherics NASDAQ: FOCL reported 26% growth in third-quarter 2026 revenue from its high-intensity focused ultrasound business, but lowered the top end of its full-year forecast after three anticipated system sales slipped into the fourth quarter.
FocalTherics Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U. S. Procedure Volume Year-to-date AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the "Company"1), a global leader in robotic focal therapy, today announced financial results for the third quarter of 2026.
Benchmark FOCL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for EDAP TMS S.A. American Depositary Shares (FOCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.84 | $106.45M | -3.23 | 2.01% | -59.75% | -241.01% | — | |
| $11.06 | $138.18M | -47.18 | 14.52% | -7.12% | -74.71% | — | |
| $430.53 | $152.1B | 51.19 | 20.51% | 25.54% | 16.91% | — | |
| $11.14 | $1.29B | -10.69 | 8.28% | -16.78% | -35.81% | — | |
| $89.67 | $2.95B | -76.92 | 26.24% | -4.52% | -22.8% | — | |
| $243.25 | $14.35B | -87.67 | 32.33% | -24.6% | -24.91% | — |
EDAP TMS S.A. American Depositary Shares (FOCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
EDAP TMS S.A. American Depositary Shares (FOCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Aug 19, 2026·SEC
Aug 14, 2026·SEC
Mar 25, 2026·SEC
Get notified when FOCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EDAP TMS S.A. American Depositary Shares (FOCL) stock FAQ — growth, dividends, profitability & financials explained
EDAP TMS S.A. American Depositary Shares (FOCL) reported $62.8M in revenue over the trailing twelve months. Revenue was $70.7M in fiscal year 2025. That is 116% more than the $32.7M of fiscal year 1997.
EDAP TMS S.A. American Depositary Shares (FOCL) revenue fell by 10.8% over the trailing twelve months, compared with the twelve months before.
No. EDAP TMS S.A. American Depositary Shares (FOCL) reported a net loss of $37.5M over the trailing twelve months.
EDAP TMS S.A. American Depositary Shares (FOCL) had a return on equity (ROE) of -241.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
EDAP TMS S.A. American Depositary Shares (FOCL) had negative free cash flow of $3.7M over the trailing twelve months.